PMLive2d
Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis
Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing ...
GlobalData on MSN4d
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints
All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.
Fierce Biotech4d
Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
BioSpace3d
Amgen, Kyowa Kirin’s Rocatinlimab Picks Up Steam With Late-Stage Atopic Dermatitis Win
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
Pharmabiz3d
Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis
Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...
Amgen, Kyowa announces new results from ongoing ROCKET Phase 3 study
Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...
J.P. Morgan Sticks to Its Hold Rating for Kyowa Kirin Co (KYKOF)
In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Kyowa Kirin Co (KYKOF – Research Report), with a ...
Morningstar6d
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...